Skip to content

Clinical observation of moxibustion in the treatment of oligoasthenoteratozoospermia

Clinical observation of acupuncture and moxibustion in the treatment of idiopathic oligoasthenoteratozoospermia based on the "Fuyang theory"

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085056
Enrollment
Unknown
Registered
2024-05-30
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oligoasthenoteratozoospermia

Interventions

Moxibustion:At the "Guan Yuan" wheat moxibustion treatment, each time 9. The high proportion of moxa wool is made into 5mg/one wheat-like moxa, and after disinfection, an appropriate amount of petrole

Sponsors

Yangzhou Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
22 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1)? sperm concentration < 15× 10^6/ml; Total sperm count < 39× 10^6/ml; ? PR < 32% or PR+NP < 40%; ? Normal sperm morphology < 4%; . (2) Male between the ages of 22 (inclusive) ~ 40 years old (inclusive). (3) No male infertility related treatment within two weeks. (4) Agree to participate in clinical trials and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Male infertility caused by congenital malformations of the genital tract or organic diseases of the urinary system such as vas deferens obstruction; (2) Allergic constitution, known to be allergic to the drug components in this study; (3) Have serious primary heart, liver, lung, kidney, blood or serious diseases that affect their survival; (4) According to the judgment of the investigator, there are other pathologies that reduce the possibility of enrollment or complicate enrollment, such as frequent changes in the working environment, which are easy to cause loss to follow-up; (5) Patients who are participating in clinical trials of other drugs;

Design outcomes

Primary

MeasureTime frame
Sperm quality analysis;

Secondary

MeasureTime frame
DFI;Serum sex hormone levels;Safety Assessment;Pregnancy rate;

Countries

China

Contacts

Public ContactQiu Shuo

Yangzhou Hospital of Traditional Chinese Medicine

jamesdatto@qq.com+86 181 1825 6591

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026